keyword
https://read.qxmd.com/read/38471525/medicinal-use-of-different-cannabis-strains-results-from-a-large-prospective-survey-in-germany
#1
JOURNAL ARTICLE
Natalia Szejko, Eva Becher, Florian Heimann, Franjo Grotenhermen, Kirsten R Müller-Vahl
BACKGROUND: Up to now, it is unclear whether different medicinal cannabis (MC) strains are differently efficacious across different medical conditions. In this study, the effectiveness of different MC strains was compared depending on the disease to be treated. METHODS: This was an online survey conducted in Germany between June 2020 and August 2020. Patients were allowed to participate only if they received a cannabis -based treatment from pharmacies in the form of cannabis flowers prescribed by a physician...
March 12, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/36986731/digital-technologies-applied-to-control-the-one-step-process-of-cannabis-olive-oil-preparations
#2
JOURNAL ARTICLE
Paolo Bongiorno, Antonio Lopalco, Antonella Casiraghi, Antonio Spennacchio, Alessandro Pitruzzella, Angela Assunta Lopedota, Paola Minghetti, Nunzio Denora
The reproducibility of an extemporaneous preparation is an essential condition for guaranteeing the quality, efficacy, and safety of the medicinal product. This study aimed to develop a controlled one-step process for cannabis olive oil preparations by applying digital technologies. For this purpose, the chemical profile of cannabinoid contents in oil extracts of Bedrocan, FM2, and Pedanios varieties obtained with the already in use method, proposed by the Italian Society of Compounding Pharmacists (SIFAP), was compared with two new methods, specifically the Tolotto Gear® extraction method (TGE) and the Tolotto Gear® extraction method preceded by a pre-extraction procedure (TGE-PE)...
March 8, 2023: Pharmaceutics
https://read.qxmd.com/read/36725378/inhaled-%C3%AE-9-tetrahydrocannabinol-does-not-enhance-oxycodone-induced-respiratory-depression-randomised-controlled-trial-in-healthy-volunteers
#3
RANDOMIZED CONTROLLED TRIAL
Cornelis Jan van Dam, Rutger van der Schrier, Monique van Velzen, Maarten van Lemmen, Pieter Simons, Kiki W K Kuijpers, Simone Jansen, Mikael A Kowal, Erik Olofsen, Cornelis Kramers, Albert Dahan, Marieke Niesters
BACKGROUND: In humans, the effect of cannabis on ventilatory control is poorly studied, and consequently, the effect of Δ9 -tetrahydrocannabinol (THC) remains unknown, particularly when THC is combined with an opioid. We studied the effect of THC on breathing without and with oxycodone pretreatment. We hypothesised that THC causes respiratory depression, which is amplified when THC and oxycodone are combined. METHODS: In this randomised controlled crossover trial, healthy volunteers were administered inhaled Bedrocan® 100 mg (Bedrocan International B...
April 2023: British Journal of Anaesthesia
https://read.qxmd.com/read/36655645/oral-thc-cbd-cannabis-extract-in-main-symptoms-of-alzheimer-disease-agitation-and-weight-loss
#4
B Palmieri, M Vadalà
OBJECTIVES: Ten million new cases of dementia are recorded annually worldwide, with agitation and idiopathic weight loss being the most common symptoms. Several pharmacological therapies have emerged in recent years, but the clinical use of cannabis extracts in older patients with AD is constantly growing. This retrospective, analytical, observational, spontaneous trial aimed to enhance the clinical action of THC: CBD cannabis extract administration in AD patients with severe symptoms such as agitation, weight loss, cognitive impairment, and sleep disturbance...
2023: La Clinica Terapeutica
https://read.qxmd.com/read/36559212/ultrasound-assisted-extraction-of-cannabinoids-from-cannabis-sativa-for-medicinal-purpose
#5
JOURNAL ARTICLE
Antonella Casiraghi, Andrea Gentile, Francesca Selmin, Chiara Grazia Milena Gennari, Eleonora Casagni, Gabriella Roda, Gloria Pallotti, Pierangela Rovellini, Paola Minghetti
Over the past 20 years, the interest in Cannabis oily extracts for medicinal use compounded in pharmacy has consistently grown, along with the need to have preparations of adequate quality. Hot maceration (M) is the most frequently used method to compound oily solutions. In this work, we systematically studied the possibility of using an ultrasonic homogenizer and a sonotrode (US) as an alternative extraction method. Oily solutions were prepared using two available varieties of Cannabis for medicinal use, called FM2 and Bedrocan...
December 5, 2022: Pharmaceutics
https://read.qxmd.com/read/35665680/a-description-of-cannabinoid-levels-in-cannabis-oil-by-high-performance-liquid-chromatography-mass-spectrometry-in-a-reference-laboratory-of-north-italy
#6
JOURNAL ARTICLE
Alessandra Manca, Alice Palermiti, Jacopo Mula, Elisa Delia De Vivo, Sandra Zeaiter, Marco Simiele, Amedeo De Nicolò, Marco Cantù, Jessica Cusato, Antonio D'Avolio
BACKGROUND: Cannabis oils from FM2®, Bedica®, Bediol®, Bedrocan®, Bedrolite® and Pedanios 22/1® are largely used for medical purposes such as spasticity, chronic pain and appetite stimulating. Several studies showed cannabinoids action on CB1 and CB2 receptors reduces the hyperalgesic phase in inflammatory pain, leading to an improvement of conditions. The active compounds of these galenic preparations show a high variability making titration mandatory. For this reason, the exact oil composition knowledge is fundamental for personalizing therapy...
May 28, 2022: Phytomedicine
https://read.qxmd.com/read/34575932/neuroprotective-effects-of-cannabidiol-but-not-%C3%AE-9-tetrahydrocannabinol-in-rat-hippocampal-slices-exposed-to-oxygen-glucose-deprivation-studies-with-cannabis-extracts-and-selected-cannabinoids
#7
JOURNAL ARTICLE
Elisa Landucci, Costanza Mazzantini, Daniele Lana, Pier Luigi Davolio, Maria Grazia Giovannini, Domenico E Pellegrini-Giampietro
(1) Background: Over the past 10 years, a number of scientific studies have demonstrated the therapeutic potential of cannabinoid compounds present in the Cannabis Sativa and Indica plants. However, their role in mechanisms leading to neurodegeneration following cerebral ischemia is yet unclear. (2) Methods: We investigated the effects of Cannabis extracts (Bedrocan, FM2) or selected cannabinoids (Δ9 -tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol) in rat organotypic hippocampal slices exposed to oxygen-glucose deprivation (OGD), an in vitro model of forebrain global ischemia...
September 9, 2021: International Journal of Molecular Sciences
https://read.qxmd.com/read/34567876/a-systematic-review-of-fibromyalgia-and-recent-advancements-in-treatment-is-medicinal-cannabis-a-new-hope
#8
REVIEW
Hajra Khurshid, Israa A Qureshi, Nasrin Jahan, Terry R Went, Waleed Sultan, Alisha Sapkota, Michael Alfonso
Fibromyalgia syndrome (FMS) is a pain disorder characterized by chronic widespread pain, fatigue, and sleep disturbance, in the absence of any well-defined underlying organic disease. The exact pathophysiology and the mechanism which links different factors related to the disease is still unknown. Due to unknown precise pathogenesis, the coexistence of other diseases, and overlapping clinical features, FMS diagnosis may be laborious. Various treatment strategies are used, only a few Food and Drug Administration (FDA) approved, still we are facing challenges regarding effective treatment...
August 2021: Curēus
https://read.qxmd.com/read/34347088/oral-cannabinoid-preparations-for-the-treatment-of-chronic-migraine-a-retrospective-study
#9
JOURNAL ARTICLE
Carlo Baraldi, Flavia Lo Castro, Andrea Negro, Anna Ferrari, Maria Michela Cainazzo, Luca Pani, Simona Guerzoni
OBJECTIVE: To explore the effectiveness and safety of three oral cannabinoid preparations (FM2®, Istituto farmaceutico militare, Firenze, Italy; Bedrocan®, Bedrocan International, Vandaam, Netherlands; and Bediol®, Bedrocan International, Vandaam, Netherlands) in the treatment of chronic migraine. DESIGN: Retrospective, cohort study. SUBJECTS: Patients with chronic migraine who received FM2, Bedrocan, or Bediol daily for the off-label treatment of their headache, for up to 6 months...
February 1, 2022: Pain Medicine
https://read.qxmd.com/read/34062478/fast-liquid-chromatography-tandem-mass-spectrometry-method-for-the-simultaneous-determination-of-phytocannabinoids-in-oily-based-preparations
#10
JOURNAL ARTICLE
G M Merone, A Tartaglia, S Rossi, F Santavenere, E Bassotti, C D'Ovidio, M Bonelli, E Rosato, U de Grazia, A Zanardo, M Locatelli, F Savini
The reported method aims to be a powerful aid for the simultaneous determination of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) in oily based preparations. The chromatographic separation was carried out using an Hypersil Gold PFP (50 × 2.1 mm, 1.9 μm) column, using H2O + 2 mM ammonium formate + 0.2 % formic acid (M1) and Methanol + 2 mM ammonium formate + 0...
September 5, 2021: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/32629796/impact-of-lipid-sources-on-quality-traits-of-medical-cannabis-based-oil-preparations
#11
JOURNAL ARTICLE
Alberto Ramella, Gabriella Roda, Radmila Pavlovic, Michele Dei Cas, Eleonora Casagni, Giacomo Mosconi, Francisco Cecati, Paola Minghetti, Carlo Grizzetti
The feasibility of the use of two lipid sources and their impact on the cannabinoid profile, terpene fingerprint, and degradation products in medical cannabis oil preparations during 3 months of refrigerated storage time were investigated. LCHRMS-Orbitrap® and HS-SPME coupled to GC-MS for the investigation of targeted and untargeted cannabinoids, terpenes, and lipid degradation products in Bedrocan® and Bediol® macerated oils were used as analytical approaches. As regards the cannabinoid trend during 90 days of storage, there were no differences between PhEur-grade olive oil (OOPH) and medium-chain triglycerides oil (MCT oil) coupled to a good stability of preparations for the first 60 days both in Bedrocan® and Bediol® oils...
June 30, 2020: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/32116208/adding-medical-cannabis-to-standard-analgesic-treatment-for-fibromyalgia-a-prospective-observational-study
#12
JOURNAL ARTICLE
Valeria Giorgi, Sara Bongiovanni, Fabiola Atzeni, Daniela Marotto, Fausto Salaffi, Piercarlo Sarzi-Puttini
OBJECTIVES: To assess any clinical improvement attributable to the addition of medical cannabis treatment (MCT) to the stable (>3 months) standard analgesic treatment of fibromyalgia (FM) patients, the retention rate and any changes in the concomitant analgesic treatment over a period of six months. METHODS: The study involved 102 consecutive FM patients with VAS scores ≥4 despite standard analgesic treatment. Patients were prescribed two oil-diluted cannabis extracts: Bedrocan (22% THC, <1% CBD), and Bediol (6...
January 2020: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/30768819/spontaneous-anecdotal-retrospective-open-label-study-on-the-efficacy-safety-and-tolerability-of-cannabis-galenical-preparation-bedrocan
#13
JOURNAL ARTICLE
Beniamino Palmieri, Carmen Laurino, Maria Vadalà
OBJECTIVES: Our main aim was to investigate the short-term therapeutic effects, safety/tolerability and potential side effects of the cannabis galenical preparation (Bedrocan) in patients with a range of chronic conditions unresponsive to other treatments. METHODS: In this retrospective, 'compassionate use', observational, open-label study, 20 patients (age 18-80 years) who had appealed to our 'Second Opinion Medical Consulting Network' (Modena, Italy), were instructed to take sublingually the galenical oil twice a day for 3 months of treatment...
June 2019: International Journal of Pharmacy Practice
https://read.qxmd.com/read/30585986/an-experimental-randomized-study-on-the-analgesic-effects-of-pharmaceutical-grade-cannabis-in-chronic-pain-patients-with-fibromyalgia
#14
RANDOMIZED CONTROLLED TRIAL
Tine van de Donk, Marieke Niesters, Mikael A Kowal, Erik Olofsen, Albert Dahan, Monique van Velzen
In this experimental randomized placebo-controlled 4-way crossover trial, we explored the analgesic effects of inhaled pharmaceutical-grade cannabis in 20 chronic pain patients with fibromyalgia. We tested 4 different cannabis varieties with exact knowledge on their [INCREMENT]-tetrahydrocannabinol (THC) and cannabidiol (CBD) content: Bedrocan (22.4-mg THC, <1-mg CBD; Bedrocan International BV, Veendam, the Netherlands), Bediol (13.4-mg THC, 17.8-mg CBD; Bedrocan International BV, Veendam, the Netherlands), Bedrolite (18...
April 2019: Pain
https://read.qxmd.com/read/30580232/pharmacokinetics-of-bedrocan%C3%A2-a-cannabis-oil-extract-in-fasting-and-fed-dogs-an-explorative-study
#15
JOURNAL ARTICLE
Beata Łebkowska-Wieruszewska, Fabio Stefanelli, Silvio Chericoni, Helen Owen, Amnart Poapolathep, Andrzej Lisowski, Mario Giorgi
The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design. The quantification of the two active ingredients was performed by LC/MS. No detectable concentrations of CDB were found at any collection time...
April 2019: Research in Veterinary Science
https://read.qxmd.com/read/29247961/comprehensive-quality-evaluation-of-medical-cannabis-sativa-l-inflorescence-and-macerated-oils-based-on-hs-spme-coupled-to-gc-ms-and-lc-hrms-q-exactive-orbitrap%C3%A2-approach
#16
COMPARATIVE STUDY
Lorenzo Calvi, Daniela Pentimalli, Sara Panseri, Luca Giupponi, Fabrizio Gelmini, Giangiacomo Beretta, Davide Vitali, Massimo Bruno, Emanuela Zilio, Radmila Pavlovic, Annamaria Giorgi
There are at least 554 identified compounds in C. sativa L., among them 113 phytocannabinoids and 120 terpenes. Phytocomplex composition differences between the pharmaceutical properties of different medical cannabis chemotype have been attributed to strict interactions, defined as 'entourage effect', between cannabinoids and terpenes as a result of synergic action. The chemical complexity of its bioactive constituents highlight the need for standardised and well-defined analytical approaches able to characterise the plant chemotype, the herbal drug quality as well as to monitor the quality of pharmaceutical cannabis extracts and preparations...
February 20, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/29072720/cannabis-through-the-looking-glass-chemo-and-enantio-selective-separation-of-phytocannabinoids-by-enantioselective-ultra-high-performance-supercritical-fluid-chromatography
#17
JOURNAL ARTICLE
G Mazzoccanti, O H Ismail, I D'Acquarica, C Villani, C Manzo, M Wilcox, A Cavazzini, F Gasparrini
By using the Inverted Chirality Columns Approach (ICCA) we have developed an enantioselective UHPSFC method to determine the enantiomeric excess (ee) of (-)-Δ9 -THC in medicinal marijuana (Bedrocan®). The ee was high (99.73%), but the concentration of the (+)-enantiomer (0.135 %) was not negligible, and it is worth a systematic evaluation of bioactivity.
November 14, 2017: Chemical Communications: Chem Comm
https://read.qxmd.com/read/29057480/cannabinoids-concentration-variability-in-cannabis-olive-oil-galenic-preparations
#18
JOURNAL ARTICLE
Chiara Carcieri, Cristina Tomasello, Marco Simiele, Amedeo De Nicolò, Valeria Avataneo, Luca Canzoneri, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio
OBJECTIVES: Knowledge of the exact concentration of active compounds in galenic preparations is crucial to be able to ensure their quality and to properly administer the prescribed dose. Currently, the need for titration of extracts is still debated. Considering this, together with the absence of a standard preparation method, the aim of this study was to evaluate cannabinoids concentrations variability in galenic olive oil extracts, to evaluate the interlot and interlaboratory variability in the extraction yield and in the preparation composition...
January 2018: Journal of Pharmacy and Pharmacology
https://read.qxmd.com/read/20118579/cannabinoid-receptor-1-binding-activity-and-quantitative-analysis-of-cannabis-sativa-l-smoke-and-vapor
#19
JOURNAL ARTICLE
Justin Fischedick, Frank Van Der Kooy, Robert Verpoorte
Cannabis sativa L. (cannabis) extracts, vapor produced by the Volcano vaporizer and smoke made from burning cannabis joints were analyzed by GC-flame ionization detecter (FID), GC-MS and HPLC. Three different medicinal cannabis varieties were investigated Bedrocan, Bedrobinol and Bediol. Cannabinoids plus other components such as terpenoids and pyrolytic by-products were identified and quantified in all samples. Cannabis vapor and smoke was tested for cannabinoid receptor 1 (CB1) binding activity and compared to pure Delta(9)-tetrahydrocannabinol (Delta(9)-THC)...
February 2010: Chemical & Pharmaceutical Bulletin
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.